Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Subject Index

Subject Index JOURNAL OF THORACIC ONCOLOGY Carboplatin, S89 A E Carcinoembryonic antigen (CEA), S85 A549 cells, S43 Early detection, S29, S50 Carcinogenesis, S37, S41 Acinar carcinoma of the lung, S54 Early diagnosis, S47 Carcinoid, S82 Activating mutation, S76 Early response assessment, S104 Cardiac toxicity, S75 Activity Based Protein Profiling, S57 Early-stage cancer, S22, S63, S67 Cavity, S99 Acute esophageal toxicity, S71 Early stage NSCLCs, S17, S18, S20 CBCT, S108 Adaptive radiotherapy, S107 EBUS-EUS, S9, S47, S58 CEA, S40 Adenocarcinoma, S26, S87, S91, S92, S110 ECOG performance status, S94 CEC, S55 Adjuvant chemotherapy, S18, S66 Effectiveness, S110 Cellsearch, S54 Adjuvant CT stage 1 NSCLC, S22 Efficacy, S80 Cetuximab, S13 Adjuvant therapy, S8 EGFR (epidermal growth factor receptor), S11, Chemo-radiotherapy, S13, S14, S30, S105 Advanced cancer, S98 S24, S35, S38, S40, S76, S87, S88 Chemotherapy, S10, S25, S73, S74, S79, S83, Advanced NSCLC, S34, S79, S82, S83, S84, EGFR gene amplification, S20 S91, S106 S85, S86, S87, S94 EGFR gene mutation, S9, S20, S38, S86 Chromosomal alteration, S48 Amifostine, S72, S75 EGFR inhibitor, S13 Circulating DNA, S42 Anaemia, S23 EGFR mutation, S41, S76, S77 Circulating tumor cells, S11, S40, S54 Angiogenesis, S51, S88 EGFR tyrosine kinase inhibitor, S85, S87 Cisplatin, S111 Angiogenesis inhibitor, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Subject Index

Journal of Thoracic Oncology , Volume 5 – May 1, 2010
Download PDF
3 pages

Loading next page...
 
/lp/wolters-kluwer-health/subject-index-05mnnAuC3r
ISSN
1556-0864

Abstract

JOURNAL OF THORACIC ONCOLOGY Carboplatin, S89 A E Carcinoembryonic antigen (CEA), S85 A549 cells, S43 Early detection, S29, S50 Carcinogenesis, S37, S41 Acinar carcinoma of the lung, S54 Early diagnosis, S47 Carcinoid, S82 Activating mutation, S76 Early response assessment, S104 Cardiac toxicity, S75 Activity Based Protein Profiling, S57 Early-stage cancer, S22, S63, S67 Cavity, S99 Acute esophageal toxicity, S71 Early stage NSCLCs, S17, S18, S20 CBCT, S108 Adaptive radiotherapy, S107 EBUS-EUS, S9, S47, S58 CEA, S40 Adenocarcinoma, S26, S87, S91, S92, S110 ECOG performance status, S94 CEC, S55 Adjuvant chemotherapy, S18, S66 Effectiveness, S110 Cellsearch, S54 Adjuvant CT stage 1 NSCLC, S22 Efficacy, S80 Cetuximab, S13 Adjuvant therapy, S8 EGFR (epidermal growth factor receptor), S11, Chemo-radiotherapy, S13, S14, S30, S105 Advanced cancer, S98 S24, S35, S38, S40, S76, S87, S88 Chemotherapy, S10, S25, S73, S74, S79, S83, Advanced NSCLC, S34, S79, S82, S83, S84, EGFR gene amplification, S20 S91, S106 S85, S86, S87, S94 EGFR gene mutation, S9, S20, S38, S86 Chromosomal alteration, S48 Amifostine, S72, S75 EGFR inhibitor, S13 Circulating DNA, S42 Anaemia, S23 EGFR mutation, S41, S76, S77 Circulating tumor cells, S11, S40, S54 Angiogenesis, S51, S88 EGFR tyrosine kinase inhibitor, S85, S87 Cisplatin, S111 Angiogenesis inhibitor,

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: May 1, 2010

There are no references for this article.